Recruiting Clinical Trials

Displaying 41 - 50 of 242 result(s)
Study Title Condition Phase Location
A Randomized, Participant- and Investigator-blinded, Placebo-controlled, Single Ascending Dose and Multiple Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of INE963 in Healthy Participants Healthy Volunteers Phase 1
  • Country: 
    United Kingdom
A First-in-patient Phase I/II Clinical Study to Investigate the Safety, Tolerability and Efficacy of Genome-edited Hematopoietic Stem and Progenitor Cells in Subjects With Severe Complications of Sickle Cell Disease Sickle Cell Disease Phase 1, Phase 2
  • Country: 
    United States
  • Country: 
    Italy
An Open-label, Multi-center Rollover Protocol for Continued Characterization of Safety and Tolerability for Subjects Who Have Participated in a Novartis-sponsored Spartalizumab Study as Single Agent or in Combination With Other Study Treatments Advanced Solid Tumors Phase 1
  • Country: 
    United States
  • Country: 
    Belgium
  • Country: 
    Canada
  • Country: 
Phase II, Open Label, Study of PHE885, a B-cell Maturation Antigen (BCMA)-Directed CAR-T Cells in Adult Patients With Relapsed and Refractory Multiple Myeloma Multiple Myeloma Phase 2
  • Country: 
    Australia
  • Country: 
    Singapore
  • Country: 
    Spain
A Phase I/Ib, Open-label, Multi-center Study of DFF332 as a Single Agent and in Combination With Everolimus or IO Agents in Patients With Advanced/Relapsed ccRCC and Other Malignancies With HIF2α Stabilizing Mutations Carcinoma, Renal Cell Phase 1
  • Country: 
    United States
  • Country: 
    Czech Republic
  • Country: 
    France
  • Country: 
A Phase I/II, Multicenter, Open-label Study of MAK683 in Adult Patients With Advanced Malignancies Diffuse Large B-cell Lymphoma Phase 1, Phase 2
  • Country: 
    United States
  • Country: 
    China
  • Country: 
    France
  • Country: 
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib Relapsing Multiple Sclerosis Phase 3
  • Country: 
    United States
  • Country: 
    Poland
  • Country: 
    Spain
A Twelve-Month, Randomized, Double-Masked, Multicenter, Phase III, Two-Arm Study Comparing the Efficacy and Safety of Brolucizumab 6 mg Versus Aflibercept in Chinese Patients With Neovascular Age-Related Macular Degeneration Neovascular Age-Related Macular Degeneration Phase 3
  • Country: 
    China
A Prospective, Observational Study to Assess the Real World Effectiveness of Inclisiran (Leqvio®) in Chinese Adult Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia Primary Hypercholesterolemia, Mixed Dyslipidemia Not Given
  • Country: 
    China
Phase I, Open-label, Multicenter Study to Evaluate the Imaging Performance, Safety, Biodistribution and Dosimetry of [68Ga]-FF58 in Adult Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins. Glioblastoma Multiforme, Brain Neoplasms, Gastroesophageal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma Phase 1
  • Country: 
    France